Comparison of the efficacy in prevention of hepatitis B virus recurrence after liver transplantation between HBIG and lamivudine

Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis

“…Of these, 931 clearly irrelevant publications were excluded. Of the 37 potentially eligible studies, 17 were excluded (20–36) (Fig. 1).…”

Hepatitis B immunoglobulins and/or lamivudine for preventing hepatitis B recurrence after liver transplantation: A systematic review

“…We retrieved the 3 papers 11–13 on 2 randomized clinical studies. The 2 studies were coded as Lee KW 2001, 11 Park SJ 2002 12 .…”

“…We retrieved the 3 papers 11–13 on 2 randomized clinical studies. The 2 studies were coded as Lee KW 2001, 11 Park SJ 2002 12 . In Lee KW 2001, 11 58 liver transplant patients due to HBV infection were allocated randomly into HBIg group ( n = 30) or combination group ( n = 28).…”

“…The 2 studies were coded as Lee KW 2001, 11 Park SJ 2002 12 . In Lee KW 2001, 11 58 liver transplant patients due to HBV infection were allocated randomly into HBIg group ( n = 30) or combination group ( n = 28). Only 43 patients (19 patients of HBIg group and 24 patients of combination group) who survived more than 90 days were included in analysis.…”

“…The 2 randomized clinical studies 11,12 were described as randomized, but none had mentioned adequate generation of allocation sequence. None of the 2 trials were labeled as double or single blind or described follow‐up and withdrawals/drop‐outs in detail.…”